Login to Your Account

Clinic Roundup

Wednesday, October 31, 2012
• Ocular Therapeutix Inc., of Bedford, Mass., reported that a Phase II study of sustained-release travoprost (OTX-TP2) for glaucoma and ocular hypertension in 20 patients produced results comparable to topical brand name ophthalmic solutions travatan (Alcon Laboratories), Lumigan (Allergan Inc.) and Xalatan (Pfizer Inc.).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription